Pyrrole & Indole

Accel Pharmtech LLC here, providing catalog chemicals, custom synthesis, contract research, process development and optimization with high quality, competitive price, timely communications and fast delivery in US.

Currently some Pyrrole & Indole compounds (inventory products)are being on promotion, such as 1-methyl-1H-Indol-5-ol  (cas# 13523-92-7) ,  1,4,6,7-tetrahydro-5H-Indol-5-one  (cas# 35419-02-4), etc.

If you are interested it, please feel free to contact us. Then detailed products will be offered.Promotion

Looking forward to your email.

Accel Pharmtech
Sam Jiang
614 Cranbury Rd. # 7085
East Brunswick, NJ 08816, USA
TEL: 1-732-993-9004
Fax: 1-732-289-6244 (24×7)
Email: sales@accelpharmtech.com
Website: http://www.accelpharmtech.com

Advertisements

The biggest pharma M&A in years

Shire and Takeda come to terms with a $64B deal

Late Tuesday, after a fifth buyout offer from Takeda, Shire said the Japanese drugmaker had finally landed on a proposal worth recommending to shareholders. It’s a cash-and-stock bid now worth $64 billion or so, about $4 billion more than its first offer.

shire

The deal still has to be approved by both boards and is subject to due diligence. The U.K.’s takeover board, which has strict rules for the timing and disclosure of bids, extended a deadline to give Takeda and Shire until May 8 to wrap it up.

Structured this way, the deal “seems to be much more of a merger,” Bernstein analyst Ronny Gal pointed out in a note to clients. Shire shareholders will receive 50% of the value of the combined company, and the companies will do reciprocal due diligence before any deal closes.

Novartis puts $100 million into malaria R&D

Novartis will spend more than $100 million over five years to develop new treatments for malaria. The funds will support clinical trials for two antimalarial drug candidates, KAF156 and KAE609, which are both in midstage clinical studies. Malaria deaths have dropped by 60% between 2000 and 2015. But the infection continues to kill more than 400,000 people each year. Novartis says it will make the drugs affordable in the countries that need them the most. (See more details on c&en)

Novartis

Tacrolimus

Tacrolimus (also FK-506 or fujimycin, trade names Prograf, Advagraf, Protopic) is an immunosuppressive drug used mainly after allogeneic organ transplant to lower the risk of organ rejection. Tacrolimus is also used in the treatment of other T cell-mediated diseases such as eczema (for which it is applied to the skin in a medicated ointment), severe refractory uveitis after bone marrow transplants, exacerbations of minimal change disease, Kimura’s disease, and the skin condition vitiligo.

CAS# 104987-11-3

Tacrolimus
Tacrolimus

This is Accel Pharmtech, LLC (DUNS number: 833130128)and we welcome all customers and vendors to cooperate business with us to achieve the greatest mutual benefits!

Ariba Network ID: AN01013471473

Email: sales@accelpharmtech.com 

Website: www.accelpharmtech.com

 

Merck’s Keytruda builds its melanoma case against Opdivo with postsurgery trial win

Merck needed a big win in melanoma to help it try to catch up to archrival Bristol-Myers Squibb. And over the weekend, it got one.

At the American Association for Cancer Research annual meeting Sunday, the New Jersey drugmaker rolled out results showing that in postsurgery patients, Keytruda cut the risk of disease recurrence or death—leading to progression-free survival in those patients—by 43% compared with placebo. At the one-year mark, 75.4% of Keytruda patients hadn’t seen their disease return, while just 61% of patients on placebo could say the same. And in those with PD-L1-positive tumors, Keytruda’s benefit was even more pronounced, paring down the recurrence risk by 46%.

Keytruda
Keytruda

Roy Baynes, Merck’s head of global clinical development, in a statement called the data “compelling” and added that they “mark an important advancement for the treatment of resected stage 3 melanoma.”  (cr: FiercePharma)

Repaglinide

Repagliflozin (Repaglinide) is a short-acting insulin secretagogue for type 2 diabetes (non-insulin-dependent) patients whose diet control, weight loss, and exercise training do not effectively control their hyperglycemia.

CAS# 135062-02-1

Repaglinide
Repaglinide

This is Accel Pharmtech, LLC (DUNS number: 833130128)and we welcome all customers and vendors to cooperate business with us to achieve the greatest mutual benefits!

Currently our 500+ kinds inventory products are being on promotion. If you are interested it, please feel free to contact us. Then detailed products will be offered.

Promotion

 

Ariba Network ID: AN01013471473

Email: sales@accelpharmtech.com 

Website: www.accelpharmtech.com

AccelPharmtech—-Promotion

Accel Pharmtech LLC here, providing catalog chemicals, custom synthesis, contract research, process development and optimization with high quality, competitive price, timely communications and fast delivery in US.

Currently our 500+ kinds inventory products are being on promotion. If you are interested it, please feel free to contact us. Then detailed products will be offered.

650AD50C74669375.F46FCC5A.jpg_recompress

Looking forward to your email.
Accel Pharmtech
Sam Jiang
614 Cranbury Rd. # 7085
East Brunswick, NJ 08816
USA
TEL: 1-732-993-9004
Fax: 1-732-289-6244 (24×7)
Email: sales@accelpharmtech.com
Website: http://www.accelpharmtech.com